Abstract
Background
This study evaluated the impact of neoadjuvant chemotherapy on the prognosis of patients with resectable colorectal liver metastasis and assessed the usefulness of Beppu’s nomogram for predicting prognosis.
Methods
This retrospective study identified 88 consecutive inpatients who underwent primary hepatic resection for colorectal liver metastasis; 58 received neoadjuvant chemotherapy and 30 underwent upfront surgery. Factors associated with recurrence-free survival were identified via univariate and multivariate analysis. Propensity score analysis using inverse probability of treatment weighting was also performed.
Results
On univariate analysis, poor recurrence-free survival was associated with multiple tumors, advanced primary tumor stage, vascular invasion by the primary tumor, a Beppu score ≥ 6, and neoadjuvant chemotherapy. On multivariate analysis, a Beppu score ≥ 6 and neoadjuvant chemotherapy were independent risk factors for recurrence. Neoadjuvant chemotherapy recipients had a higher incidence of lymph node metastasis and vascular invasion than non-recipients. Propensity score analysis revealed no significant difference in the recurrence-free survival rate between these groups.
Conclusions
Our results show the usefulness of Beppu scores for predicting the prognosis of patients with colorectal liver metastasis, but do not support the use of neoadjuvant chemotherapy in these patients.
Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis
